Pricing Log in Create free account
Saturday 17 October 2026 Export CBUS’s income statement to Excel — free account

Cibus, Inc.

CBUS Healthcare Biotechnology

Cibus, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.6 million, down 14.6% from fiscal 2024. In the quarter to June 2026, revenue grew 6.54%, EPS grew 52.5%, free cash flow grew 31.6% and total debt fell 62.1%, each against the same quarter a year earlier.

1.32 0.03 +2.33%
Market cap
$98.6M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
3/9
Altman Z
−4.83
Beneish M
−4.25
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 38.91%

Capital & Financial Ratios $m

Market Cap 98.59
Revenue 4.35
Net Income (99.62)
Free Cash Flow (46.28)
Net Debt (20.38)
Current Ratio 1.62 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (1.40) (negative: loss-making)
P/S ratio 23.31 (above 10: high)
P/B ratio 6.84 (above 6: high)
Past 5Y EPS Growth —
This Y EPS Growth 69.54% (at or above 15%: strong)
Next Y EPS Growth 24.80% (at or above 15%: strong)
Next Y revenue growth 42.76% (at or above 10%: strong)
Next 5Y EPS Growth 51.36% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 18.9×, against a ten-year median of 21.5×; over the ten years it ranged from −0.2× in 2022 to 1,965× in 2019.
P/S against its own 10 years 45.45%
10-year low 10-year high
P/B against its own 10 years 79.91%
10-year low 10-year high
EV/Sales against its own 10 years 44.21%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 33 14 10 20
Receivables 1 1 1 1
Inventory — — — —
Other — — — —
35 17 12 23
2023 2024 2025 Q'26
Payables 6 6 8 6
ST’ Debt — — — —
Other 1 3 0 0
21 20 17 14

Compound Annual Growth %

10y 5y 3y
Sales 11.08% (31.34%) 185.12%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (1.05%) (9.95%) 44.51%

Revenue $m

Mar Jun Sep Dec Year
’26 2 1 — — —
’25 1 1 1 1 4
’24 1 1 2 1 4
’23 0 0 0 1 2
’22 0 0 0 0 0
’21 4 12 8 2 26
’20 2 2 5 14 24
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (11) (9) — — —
’25 (12) (14) (12) (13) (51)
’24 (13) (17) (14) (14) (58)
’23 (2) (12) (15) (17) (46)
’22 (6) (5) (4) (4) (19)
’21 (9) (2) (3) (4) (19)
’20 (12) (13) (5) (13) (44)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (12) (9) — — —
’25 (12) (14) (12) (14) (51)
’24 (14) (17) (14) (14) (59)
’23 (2) (12) (18) (17) (51)
’22 (7) (6) (5) (4) (21)
’21 (10) (2) (3) (4) (19)
’20 (13) (14) (6) (13) (45)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.33) (0.29) — — —
’25 (1.34) (0.61) (0.44) (0.59) (2.78)
’24 (1.12) (1.14) (7.63) (0.87) (10.83)
’23 (5.45) (3.05) (1.59) (21.86) (25.95)
’22 (6.50) (2.50) (6.50) (3.00) (18.50)
’21 (13.50) (6.50) (10.00) (9.00) (39.00)
’20 (17.00) (16.50) (14.50) (18.50) (66.00)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.7
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — 463.00 441.50 177.50 120.00 102.00 6.25 6.65 2.35 1.09

Analyst estimates 2026–2028

Powerpack
High — 1,594.50 1,361.50 964.75 420.50 621.50 125.50 38.85 23.18 3.40
People
People Employees 27 35 50 75 59 55 48 183 159 118
Revenue/emp, $m 0.01 0.01 0.00 0.10 0.40 0.47 0.00 0.01 0.03 0.03
Income, $m
Income, $m Revenue 0 1 0 7 24 26 0 2 4 4
Gross margin, % 49.87 100.00 100.00 (27.19) (47.28) (9.89) 100.00 100.00 100.00 100.00
EBT (12) (26) (28) (40) (45) (29) (17) (338) (283) (132)
EBT margin, % (3,029.07) (5,114.17) (11,820.76) (542.93) (187.98) (112.36) (10,758.60) (18,582.44) (6,632.66) (3,632.10)
Net income (12) (26) (28) (40) (45) (29) (17) (338) (283) (132)
Depreciation 0 1 1 2 2 2 2 254 188 27
Per share, $
Per share, $ Revenue 1.02 1.10 0.38 11.12 35.20 34.67 0.17 0.18 0.18 0.08
Earnings (30.83) (56.00) (45.50) (60.50) (66.00) (39.00) (18.50) (25.95) (10.83) (2.78)
Cash flow (23.56) (27.61) (32.92) (48.70) (64.45) (25.10) (21.05) (4.48) (2.50) (1.11)
Capex (26.59) (1.68) (3.01) (4.53) (2.64) (0.66) (1.65) (0.42) (0.03) (0.01)
Free cash flow (50.16) (29.29) (35.93) (53.22) (67.09) (25.76) (22.70) (4.90) (2.53) (1.12)
Book value 33.47 124.11 152.19 95.27 54.42 18.86 7.86 28.45 3.97 0.48
Shares, m 0 0 1 1 1 1 1 10 23 46
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 20.73 1,068.87 1,347.02 31.52 5.99 3.07 38.97 104.23 15.15 21.88
P/B 1.29 9.45 3.40 3.68 3.88 5.65 0.85 0.65 0.70 3.65
EV/Sales 15.39 977.30 1,025.21 25.98 5.59 3.21 105.11 87.14 19.37 19.45
EV/FCF (0.61) (36.60) (10.97) (5.43) (2.93) (4.32) (0.79) (3.13) (1.40) (1.38)
Cash, $m
Cash, $m Operating cash flow (9) (13) (20) (32) (44) (19) (19) (46) (58) (51)
Capex (10) (1) (2) (3) (2) 0 (2) (4) (1) (1)
Free cash flow (20) (14) (22) (35) (45) (19) (21) (51) (59) (51)
Balance, $m
Balance, $m Working capital 3 53 89 56 33 10 2 14 (3) (5)
Total debt 2 10 18 18 19 18 13 1 31 30
Net debt (5) (47) (76) (41) (10) 3 10 (32) 17 20
Shareholders’ equity 13 57 93 63 37 14 7 293 92 22
Returns, %
Returns, % ROA (56.72) (58.52) (29.22) (38.29) (59.22) (58.10) (56.67) (94.43) (56.21) (38.80)
ROIC (93.51) (147.06) (100.70) (113.98) (101.92) (105.87) (81.50) (76.24) (147.93) (145.89)
ROE (64.67) (73.60) (36.98) (50.82) (90.23) (114.49) (158.12) (178.00) (130.38) (222.98)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Cibus, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
UNCY Unicycive Therapeutics, Inc. $100.0M — (loss-making) — (loss-making) — n/m +9.77% (above 0%: growing) 0.00% 0.00% Compare
BDTX Black Diamond Therapeutics, Inc. $100.0M — (loss-making) — (loss-making) — n/m +12.91% (above 0%: growing) 100.00% 0.00% Compare
PYPD PolyPid Ltd. $99.5M — (loss-making) — — n/m −64.96% (below 0%: shrinking) 0.00% 0.00% Compare
MIST Milestone Pharmaceuticals Inc. $98.9M — (loss-making) — (loss-making) −62.73% (below 0%: shrinking) n/m −80.81% (below 0%: shrinking) 94.28% (4,584.97%) Compare
CBUS Cibus, Inc. $98.6M — (loss-making) — (loss-making) +6.54% (above 0%: growing) n/m +31.62% (above 0%: growing) 100.00% (1,300.30%)
PMVP PMV Pharmaceuticals, Inc. $97.4M — (loss-making) — — n/m +20.27% (above 0%: growing) 0.00% 0.00% Compare
NRXS Neuraxis, Inc. $97.2M — (loss-making) — (loss-making) +115.71% (above 0%: growing) n/m +29.76% (above 0%: growing) 85.87% (110.16%) Compare
IMUX Immunic, Inc. $96.9M — (loss-making) — — n/m −26.79% (below 0%: shrinking) 0.00% 0.00% Compare
ATRA Atara Biotherapeutics, Inc. $96.9M — (loss-making) — (loss-making) −96.42% (below 0%: shrinking) n/m +52.10% (above 0%: growing) 69.68% (749.21%) Compare
Median of peers $98.2M — — −62.73% — +11.34% 34.84% 0.00%

All 614 Biotechnology stocks →

Cibus, Inc. (CBUS) key facts

  • Concern: Cibus, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.6 million, down 14.6% from fiscal 2024.
  • Cibus, Inc. (CBUS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, CBUS traded at $1.32, a market capitalization of $98.6 million.
  • Return on equity was −223.0% and debt-to-equity 0.00.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −4.83 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Cibus, Inc. (CBUS) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/CBUS · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com